Research explained
SURPASS-4: interpreting tirzepatide kidney findings
Published
What the research shows
The SURPASS-4 kidney analysis examined tirzepatide versus insulin glargine in adults with type 2 diabetes and high cardiovascular risk. It was a post hoc analysis of an open-label trial. That makes the findings useful research evidence, but different from a dedicated kidney-outcomes trial designed around that question. [1]
Study at a glance
- Participants
- People with type 2 diabetes inadequately controlled on oral medicines and high cardiovascular risk.
- Study design
- Post hoc kidney analysis of a randomized, open-label tirzepatide-versus-insulin-glargine trial.
- Published research
- Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial
Because the study did not test a compounded product, its results cannot establish the safety, effectiveness or equivalence of a preparation supplied by an individual compounding pharmacy. This article explains published research. It is not medical advice.
| Measure | Reported result or interpretation |
|---|---|
| Mean annual eGFR change | −1.4 with pooled tirzepatide versus −3.6 with insulin glargine, in mL/min/1.73 m² per year. |
| Comparator | Insulin glargine, not placebo or semaglutide. |
| eGFR | An estimate of kidney filtration, assessed over time. |
| Composite | Included filtration decline, kidney-failure outcomes and new macroalbuminuria. |
What post hoc means
A post hoc analysis examines a question using data from an already conducted study. It can reveal an important pattern, but it should be labeled so readers can distinguish it from the trial’s original central objective. The distinction is about evidentiary strength, not whether the analysis is worth reading.
Randomization remains valuable, but the number of events, measurement choices and multiple comparisons matter. A precise-looking result should not be promoted as though it answers every kidney-care question on its own.
Filtration and albuminuria are not the same measure
eGFR estimates how well the kidneys filter blood. Albuminuria refers to albumin in the urine. These measures can provide different information, and a change in one should not automatically be described as a change in the other.
A composite outcome may combine laboratory changes with clinical events. To understand it, ask which events were counted and which components drove the result. A reduction in the composite cannot simply be renamed a reduction in dialysis or death.
Understanding the slope of a kidney measure
An annual eGFR change is a rate, not the percentage of people who avoided kidney failure. The two average slopes describe how a measured estimate changed over time in the groups. They should not be converted into a promise that a reader has gained a particular number of years before dialysis.
Pooling the tirzepatide groups also has a meaning: the quoted slope is not a separate verified result for each individual strength. A consumer should not use it to infer a precise dose-response relationship. The article keeps the pooled result and the post hoc context visible so that the number does not appear stronger or more individualized than it is.
Why the comparator must stay in the headline
This analysis compared tirzepatide with insulin glargine within a specific diabetes-treatment setting. It did not directly compare tirzepatide with every kidney-protective medicine, and it did not compare two compounded formulations.
The comparator is part of the meaning of the result. Removing it can turn a nuanced study finding into a broad claim that the drug protects everyone’s kidneys. Treatment choices depend on the full clinical picture, including established kidney care.
From a research finding to an individual decision
Someone with chronic kidney disease may have different priorities and monitoring needs from a person looking only for weight management. A clinician needs the actual diagnosis, kidney function, other medicines and previous treatment response before deciding what is appropriate.
This article does not provide a dosing or medication-switching plan. A study of an approved manufacturer product also does not establish the safety or effectiveness of a pharmacy’s compounded product. Those are separate questions with separate evidence requirements.
Questions that make the evidence useful
Ask what outcome matters most in your care: glucose control, weight management, slowing disease progression, avoiding an event or improving daily symptoms. Then ask whether the evidence for the proposed intervention addresses that outcome in a similar population.
If a clinician recommends treatment, clarify the exact product and coverage before comparing cash prices. Membership fees, medication charges and monitoring may be separate; a low advertised number does not answer the clinical question.
For a different diabetes-treatment comparison, read SURPASS-2.
For medication context, see interactions.
For access questions, read insurance and treatment costs.
Questions to discuss with your clinician
- Was my condition represented in this analysis?
- Which kidney outcome would we be trying to improve?
- How does this evidence fit alongside established treatment and monitoring?
Sources
- Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial. The Lancet Diabetes & Endocrinology, 2022. PMID: 36152639.
Explore more research or read how we verify published information.